News for Catalyst Biosciences, Inc. (CBIO)

Shares of Beyond Air, Inc. XAIR fell sharply in today's pre-market trading after the company posted mixed fourth-quarter results. Beyond Air reported quarterly...

Trading for Catalyst Biosciences Inc (GYRE) has resumed after a brief pause. Investors and market watchers can now analyze the company's performance with greate

Gyre Therapeutics focuses on developing anti-inflammatory drugs for organ diseases, showing promising potential. Read more on GYRE stock here.

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update...

Dec 27, 2022 / 01:00PM GMTOperator Greetings. Welcome to the Catalyst Biosciences merger call. (Operator Instructions) Please note, this conference is being rec

GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts GNI Group Ltd., today announced...

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.

Statutory Accounts Director's Report In accordance with the Corporations Act 2001, the directors of...

Catalyst Biosciences Inc (CBIO) has seen a significant daily gain of 18.1% and a 3-month gain of 204.39%. Despite the impressive gains, the company reported a L

This presentation contains statements concerning the current plans, expectations, and strategies of GNI... | May 22, 2023

Please be advised that Catalyst Biosciences, Inc. , one of our affiliates, filed 8-K to SEC today regarding its listing status at Nasdaq. For more details, please... | May 6, 2023

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33%

For RGA Investment Advisors, the third quarter saw a continuation of the ugly trend from the first half of the year. Click here to read the full fund letter.

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

Read Stock Analysts’ Updated EPS Estimates for June 1st (ARCO, AROW, ASO, BKE, BOOM, BYPLF, CALM, CARG, CBIO, CVCO) at ETF Daily News